FDA Pearson Implementation Faces Further Congressional Criticism
This article was originally published in The Tan Sheet
Executive Summary
FDA's progress in implementing the Pearson v. Shalala court decision is sharply criticized by Republican Reps. Helen Chenoweth-Hage (Idaho), Ron Paul (Texas) and Bob Stump (Ariz.) in a March 17 letter to the agency.
You may also be interested in...
FDA 100-Day Health Claim Review Provided In House Bill
FDA would be required to authorize general health claims and "claims based on government statements" within 100 days of receipt under the "Consumer Freedom Protection Act." Currently, the agency has 540 days to review a proposed health claim.
Health Claims Based On Varying Levels Of Evidence Need Distinctions - FDA
An issue FDA aims to address at the April 4 public meeting on implementation of the Pearson v. Shalala court decision is how best to convey to consumers that certain dietary supplement health claims do not have as much scientific support as other claims.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC